Global Information
회사소개 | 문의 | 비교리스트

펩티드 마이크로어레이 시장 : 성장, 동향, COVID-19의 영향 및 예측(2021-2026년)

Peptide Microarray Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2022년 01월 상품코드 1005813
페이지 정보 영문 배송안내 2-3일 (영업일 기준)
가격
US $ 4,750 ₩ 6,364,000 PDF & Excel (Single User License)
US $ 5,250 ₩ 7,033,000 PDF & Excel (Team License: Up to 7 Users)
US $ 6,500 ₩ 8,708,000 PDF & Excel (Site License)
US $ 8,750 ₩ 11,723,000 PDF & Excel (Corporate License)


펩티드 마이크로어레이 시장 : 성장, 동향, COVID-19의 영향 및 예측(2021-2026년) Peptide Microarray Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
발행일 : 2022년 01월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

펩티드 마이크로어레이 시장 규모는 예측 기간 중 5%의 CAGR로 확대할 것으로 예측됩니다.

펩티드 마이크로어레이와 단백질은 임상 어세이와 프로테오믹스의 새로운 툴이며, 대규모 단백질의 기능을 결정하는 하이스루풋(High throughput) 방법입니다. 치료법의 개발에는 SARS-CoV-2 감염 프로세스와 COVID-19의 진행에서의 역할을 정확하게 이해할 필요가 있습니다. 프로테오믹스 분야에는 이 과제로 향하는데 필요한 테크놀러지가 갖춰지고 있습니다.

2020년 10월에 Journal of Proteins and Proteomics에 게재된 기사에서 연구자는 프로테옴 기술의 개발이 코로나바이러스 팬데믹에 대한 대처를 가속할 뿐만 아니라 현재의 COVID-19 위기에 대한 대처에도 도움이 된다고 강조하고 있습니다.

펩티드 마이크로어레이는 생물의학에서 High Throughput Screening 툴로서 사용되는 다른 패턴의 수천개의 펩티드를 포함한 단백질간 상호작용의 결합 특성을 연구하기 위해 사용됩니다.

따라서 암의 부담 증가와 기술의 진보는 조사 대상 시장을 세계에서 추진하고 있는 주요 요인입니다. 또한 만성질환의 유병률 상승은 펩티드 마이크로어레이 시장에 한층 더 기여합니다. 예를 들면 NCCDPHP(National Centre for Chronic Disease Prevention and Health Promotion)에 따르면 미국 인구 약 3억 3000만 명에서 매년 성인 10명 중 6명이 만성질환을 앓고 있습니다. 이에 따라 진단 테스트를 추진하는 것은 펩티드 마이크로어레이 시장을 추진합니다.

펩티드 마이크로어레이 시장에 대해 조사했으며, 시장의 개요와 유형별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 시장 촉진요인
    • 만성질환의 부담 증대
    • 진단 검사의 기술 진보
  • 시장 억제요인
    • 상환 문제
  • Porter's Five Forces 분석

제5장 시장 세분화

  • 유형별
    • 계기
    • 시약
    • 서비스
  • 최종사용자별
    • 병원
    • 제약회사 및 바이오테크놀러지 기업
    • 연구·학술기관
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 기타 지역

제6장 경쟁 구도

  • 기업 개요
    • Arrayit Corporation
    • JPT Peptide Technologies
    • ProImmune Ltd
    • Merck KGaA
    • Terra Universal Inc
    • PEPperPRINT
    • Thermo Fischer Scientific(Affymetrix)
    • Bio-Rad Laboratories
    • Terra Universal Inc
    • LC Sciences
    • Grace Bio-Labs
    • Creative Biolabs

제7장 시장 기회 및 향후 전망

KSA 21.06.07

The Peptide Microarray Market is expected to register a CAGR of 5% during the forecast period.

Peptide microarrays and protein, the emerging tools for clinical assays and proteomics, are high-throughput methods that decide the function of proteins on a large scale. The development of therapeutics requires an accurate understanding of the role in the SARS-CoV-2 infection process and progression of COVID-19. The field of proteomics is equipped with the technologies that are required to help face this challenge.

In an article published in October 2020 in the Journal of Proteins and Proteomics, researchers have highlighted that developments in proteome technologies will not only accelerate progress in addressing the coronavirus pandemics but will also help to tackle the current COVID-19 crisis.

A peptide microarray is used to study the binding properties of protein-protein interaction that comprises thousands of peptides in distinct patterns that will be used as a high throughput screening tool in biomedical science.

Therefore the increasing burden of cancer and technological advancement are the major factors that are driving the studied market globally. Moreover, the rising prevalence of chronic diseases will further contribute to the peptide microarray market. For instance, according to the National Centre for Chronic Disease Prevention and Health Promotion (NCCDPHP), the United States has a population of about 330 million, of which 6 in 10 adults have chronic diseases each year. Thus, promoting diagnosis testing will propel the peptide microarray market.

Furthermore, rising molecular-based diagnostics techniques demand with the advancement in the technology of diagnostic testing dominant the peptide microarray market.

Key Market Trends

The Instrument Segment is Expected to Hold a Major Market Share in the Peptide Microarray Market

The instrument​ segment is expected to witness good growth in the market and is anticipated to show a similar trend over the forecast period, owing to technologically advanced peptide microarray products and various types of research in chronic disorders, such as cancer, autoimmune and infectious disease. For instance, PEPperPRIINT offers PEPperCHIP Standard Peptide Microarrays, which cover epitopes, antigens, and viral proteomics, and is widely used in various types of researches (allergen, cancer, and signature discovery).

Moreover, these are also used for antibody epitope mapping, biomarker discovery, immune monitoring, detection, and validation for protein interaction. For instance, JPT Peptide Technologies has a product PepStar Peptide Microarrays, which helps in enzyme profiling and identifies a substrate for orphan enzymes.

The research and development of peptide products are increasing as they are cost-effective, efficient, and have lower toxicity. These peptides play a major part in the COVID-19 related research. In 2020, PEPperPRINT launched the coronavirus research product PEPperCHIP Pan-Corona Spike Protein Microarray, which will give researchers access to serologically screen human coronavirus spike proteins in one assay. Hence, these factors will fuel the growth of the studied market.

North America is Expected to Hold a Significant Share in the Market and Expected to do the Same in the Forecast Period

North America is expected to dominate the global peptide microarray market due to the increasing healthcare expenditure and the presence of well-developed healthcare infrastructure. For instance, a report was published in July 2019 by MDPI wherein the Zika virus disease infected several territories in North America. The research was carried out using a peptide microarray to find the best candidates for T-B cells epitopes by immunoinformatic approach.

The growing chronic disease complexities are expected to enhance the demand for early diagnosis of the disease in the hospitals, thereby increasing the use of diagnostic capabilities, which is expected to boost the usage of peptide microarrays. According to Globocan 2020, the estimated incidence of new cancer cases was 2,281,658, and the number of deaths was 612,390 due to cancer in 2020 in the United States. The most common cancers in the United States were breast, lung, prostate, and colon (101,809). The high cancer burden will surge the demand for peptide microarray.

Moreover, rising molecular-based diagnostic techniques and increasing awareness among the population are also fueling the growth of the overall regional market.

Competitive Landscape

Some companies currently dominating the market include Merck KGaA, ProImmune Ltd, JPT Peptide Technologies, Terra Universal Inc., and Arrayit Corporation.

The market players are expanding their market position by adopting various strategies, such as acquisitions and mergers and research collaborations, while several others are introducing new products to increase their presence in the market. For instance, in 2020, JPT peptide technologies accelerated the development of a broad collection of SARS-CoV-2 PepMix Peptide Pools that would span the most relevant antigens to address cellular immunity. JPT developed a Pan-Coronavirus RepliTope Peptide Microarray spanning the entire SARS-CoV-2 proteome and selected antigens of MERS-CoV, Common Cold Coronaviruses, and SARS-CoV for profiling humoral immune responses.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Chronic Diseases
    • 4.2.2 Technological Advancements in Diagnostic Testing
  • 4.3 Market Restraints
    • 4.3.1 Reimbursement Issues
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Instruments
    • 5.1.2 Reagents
    • 5.1.3 Services
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Pharmaceutical and Biotechnology Companies
    • 5.2.3 Research and Academic Institutes
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Arrayit Corporation
    • 6.1.2 JPT Peptide Technologies
    • 6.1.3 ProImmune Ltd
    • 6.1.4 Merck KGaA
    • 6.1.5 Terra Universal Inc.
    • 6.1.6 PEPperPRINT
    • 6.1.7 Thermo Fischer Scientific (Affymetrix)
    • 6.1.8 Bio-Rad Laboratories
    • 6.1.9 Terra Universal Inc.
    • 6.1.10 LC Sciences
    • 6.1.11 Grace Bio-Labs
    • 6.1.12 Creative Biolabs

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q